16-fluoroestradiol has been researched along with Atypical Endometrial Hyperplasia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Okazawa, H; Tsujikawa, T; Tsuyoshi, H; Yamada, S; Yoshida, Y | 1 |
| Fujibayashi, Y; Kobayashi, M; Mori, T; Okazawa, H; Tsuchida, T; Tsujikawa, T; Yoshida, Y | 1 |
2 other study(ies) available for 16-fluoroestradiol and Atypical Endometrial Hyperplasia
| Article | Year |
|---|---|
Predictive Value of 16α-[18F]-Fluoro-17β-Estradiol PET as a Biomarker of Progestin Therapy Resistance in Patients With Atypical Endometrial Hyperplasia and Low-Grade Endometrial Cancer.
Topics: Adult; Endometrial Hyperplasia; Endometrial Neoplasms; Estradiol; Female; Humans; Positron-Emission Tomography; Progestins; Radiopharmaceuticals | 2019 |
Distinctive FDG and FES accumulation pattern of two tamoxifen-treated patients with endometrial hyperplasia.
Topics: Aged; Aged, 80 and over; Endometrial Hyperplasia; Estradiol; Female; Fluorodeoxyglucose F18; Humans; Positron-Emission Tomography; Radiopharmaceuticals; Tamoxifen; Tissue Distribution | 2008 |